2024 International Congress » Parkinson's Disease: Molecular Mechanisms of Disease

A novel single-cell reporter identifies regulators of the endogenous PINK1-Parkin mitochondrial quality control pathway

J. Thayer, X. Huang, J. Hawrot, D. Ramos, M. Ward, D. Narendra (BETHESDA, USA)

Age and Parkinson’s disease: clinical and biomarkers profiling of younger and older patients

G. Di Lazzaro, F. Paolini Paoletti, G. Bellomo, T. Schirinzi, P. Grillo, G. Giuffrè, A. Picca, M. Petracca, AR. Bentivoglio, NB. Mercuri, L. Parnetti, P. Calabresi (Rome, Italy)

Age- and Sex-Associated Changes in the Behavior of Neuronal Mitochondria During Healthy Aging

E. Klinman, A. Yoo (St Louis, USA)

Alpha-synuclein affects PRMT5-mediated cytoprotective pathway in neuronally differentiated SH-SY5Y cell

T. Nakamura, N. Sugeno, T. Hasegawa, K. Ikeda, S. Yoshida, S. Ishiyama, K. Sato, A. Takeda, M. Aoki (Sendai, Japan)

Alpha-Synuclein and Mitochondria Quality Control in Parkinson’s Disease: A Literature Review

L. Shen (State College, USA)

Association of Retinol Binding Protein (RBP) and the Risk of Parkinson’s disease (PD): A Narrative Literature Review

V. Sharma (Urban, India)

Bright Light Therapy: A Novel Non-Pharmacological Approach to Parkinson’s Disease

QK. Lv, YR. Sun, F. Wang, CF. Liu (Suzhou, China)

Chronic Sleep Fragmentation Accelerates the Onset of Prodromal Symptoms and Pathology in Parkinson’s Disease Model Mice

M. Miyazaki, H. Yagihara, H. Fujita, H. Yamakado, K. Wada, E. Minakawa (Kodaira, Japan)

Consistent downregulation of rarely reported antioxidant genes viz., GGL, TR, TrX, HO-1, GR, GS, in the mid brain regions among mice and Drosophila exposed to Parkinsonian toxins: Scope as early diagnostic markers

G. Chandran, R. D'Silva, A. Ashok (Mysuru, India)

Cross-Omics Clustering Identifies Common Molecular Patterns in Parkinson’s Disease

M. Lai, B. Benitez (Boston, USA)

Deciphering the Role of Auranofin-Loaded Nanoparticles Against Rotenone Model of Parkinson’s Disease: Via GSK-3β/ Nrf2/HO-1 Signaling Pathways

D. Soni, P. Kumar (Bathinda, India)

Declining Lymphocyte Count and Lymphocyte-to-Neutrophil Ratio Following Parkinson’s Disease Diagnosis.

J. Kenny, R. Torricelli, A. Zirra, A. Noyce, D. Gallagher, T. Periñán, C. Budu, T. Boyle, KC. Dey (London, United Kingdom)

Differences in Molecular and Ultrastructural profiles of astroglia and microglia in substantia nigra of two different mice strains in normal aging and experimental Parkinsonism

P. Alladi, A. Abhilash, U. Bharti, R. Santhosh Kumar, M. Philip, B. Chandrasekhar Sagar (Bangalore, India)

Discriminating alpha-synuclein strains in Parkinson’s disease

I. Schniewind, S. Bräuer, E. Dinter, BH. Falkenburger (Dresden, Germany)

Distinct Gut Microbiome in Parkinson’s disease Based on the Presence of Premotor Rapid-Eye Movement Sleep Behavior Disorders: Exploring the Alpha-synuclein

S. Jo, J-Y. Lee, J. Lee, J-W. Bae, SJ. Chung (Seoul, Republic of Korea)

Dysregulated Anti-Viral Response in LRRK2 Mice Following Infection with H1N1 Influenza Induces DA Neuron Loss in the SNpc.

K. Crowther, R. Smeyne, E. Kozina (Philadelphia, USA)

Exercise Mitigates DNA Methylation Changes at cg17274742 Associated with the Circadian Gene Variant PER2 rs2304672: A Biobank Analysis

YC. Chen, SL. Wu, YP. Liaw (Changhua, Taiwan)

Exercise-induced angiogenesis and midbrain neuroprotection in a mouse model of experimental PD

T. Rodriguez, R. Smeyne, M. Smeyne (Philadelphia, USA)

Exploring the Therapeutic Target for Lewy Body Disease using gba1 Knock-out Medaka

E. Nakanishi, T. Taguchi, M. Sawamura, N. Uemura, H. Yamakado, R. Takahashi (kyoto, Japan)

Functionality Analysis of Immunoregulatory Cells Stimulated with Dopaminergic Agonists in People Living with Parkinson’s Disease

AY. Regalado-Mustafá, DD. álvarez-Luquín, A. Guevara-Salinas, MA. Bravo-Martinez, EJ. Gallegos-Altamirano, CF. álvarez-Hernández, E. Ichikawa-Escamilla, AM. Peralta-Maza, V. Morales-Ruiz, EE. Sevilla-Reyes, JI. Velasco-Velázquez, JE. Estudillo-Hernández, M. Rodríguez-Violante, LV. Adalid-Peralta (Mexico City, Mexico)

Genetic signatures stratify PwP into three subgroups with differing responses in two disease-modifying Phase 3 trials and indicate multiple disease biology pathways to Parkinson’s Disease

K. Hill, J. Cooper, J. Kozlowska, N. Olsen, R. Sultana, J. Surmeier, R. Wyse, N. Humphryes-Kirilov, A. Cooper (Sydney, Australia)

Gut Microbial Metabolites and Future Risk of Parkinson’s Disease: A Metabolome-wide Association Study

Y. Zhao, Y. Lai, S. Darweesh, B. Bloem, L. Forsgren, J. Hansen, JM. Huerta, M. Guevara, C. Lill, G. Miller, S. Peters, R. Vermeulen (Utrecht, Netherlands)

Gut Microbiota May Alter Glucose Metabolism in Patients with Parkinson’s Disease

ST. Tsai, MK. Lu, CH. Tsai, Y. Aoh, ZL. Lai, YY. Hsu, DS. Chao, PR. Hsueh (Taichung, Taiwan)

Identification of Pre-Diagnostic Biomarkers for Parkinson’s Disease from Plasma Proteome

M. Ta, E. Appleton, S. Khosousi, A. Sturchio, I. Markaki, W. Paslawski, C. Blauwendraat, M. Nalls, A. Singleton, P. Svenningsson, H. Iwaki (Bethesda, USA)

ilex Paraguariensis (Yerba mate) modulates the AMPK pathway and downstream key metabolic mechanism that may explain its neuroprotective role.

J. Ferrario, H. Hauche, L. Tschopp, T. Eidelman, M. Bordone (Buenos Aires, Argentina)

Immunoproteasome subunits as emerging contributors to neurodegeneration in Parkinson’s Disease

HD. Nguyen, YE. Kim (Anyang-si, Gyeonggi-do, Republic of Korea)

Insulin-like growth factor 2 and inflammatory response in Parkinson Disease: Potential predictor marker

CA. Aguilera, FG. Grünenwald, VU. Urbina, EL. Larraechea, RLV. Vidal (Santiago, Chile)

Interaction of GCase and ganglioside GM1 in the aggregation of α-Synuclein

F. Fierli, G. Uras, S. Lucas-Del Pozo, S. Koletsi, V. Lentini, M. Toffoli, P. Caboni, A. Schapira (London, United Kingdom)

Investigating the pathogenesis of GBA1-associated Parkinson’s disease using GBA1 isogenic iPSC lines

Y. Chen, C. Chen, C. Ma, J. Lichtenberg, E. Hertz, T. Jong, R. Sam, Y. Li, S. Vrisjen, P. Vangheluwe, C. Blauwendraat, E. Sidransky (Bethesda, USA)

iPLA2β controls ER-mitochondria tethering and Ca2+ transfer in Parkinson’s disease

ZH. Lin, Y. Liu, NJ. Xue, BR. Zhang, JL. Pu (Hangzhou, China)

LRRK2 G2019S mutant damages mitochondrial transfer by a Drp1-STX17 depend pathway in Parkinson’s disease

X. Cheng (Suzhou, China)

LRRK2 I1371V Mutation: Unraveling Pathogenic Mechanisms in Dopaminergic Neurons via Membrane Fluidity & Calcium Dysregulation using PD Patient iPSCs

I. Datta, S. Jagtap, V. Holla, N. Kamble, R. Yadav, P. Pal (Bengaluru, India)

LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Pathologic Alpha-Synuclein: Clinical and Biomarker Characterization

L. Chahine, D. Lafontant, C. Choi, H. Iwaki, M. Brumm, R. Alcalay, K. Nudelman, A. Dagher, K. Merchant, A. Vo, Q. Tao, C. Venuto, K. Kieburtz, K. Poston, S. Bressman, P. Gonzalez Latapi, B. Avants, C. Coffey, D. Jennings, E. Tolosa, A. Siderowf, K. Marek, T. Simuni (Pittsburgh, USA)

Measures of Mitochondrial Function in Serum across the Parkinson’s Disease Spectrum

L. Neilson, J. Elliott, M. Lim, N. Gray (Portland, USA)

Melatonin Modulates NLRP3 Inflammasome Activation through TLR2 to Protect Against Parkinson’s Disease

XY. Wang, JW. Li, HS. Liu, XN. Xiong (Wuhan, China)

Metabolic Regulators of Mitochondrial DNA Release in Cellular Models of PRKN-linked Parkinson’s Disease

G. Agyeah, J. Ghelfi, L. Gallucci, A. Rakovic, P. Antony, S. Pereira, A. Grünewald (Belval Esch-sur-Alzette, Luxembourg)

Neuronal Exosome based markers in Parkinson’s Disease and Progressive Supranuclear Palsy

A. Roy, S. Brahmachari, A. Pantelyat, L. Rosenthal, V. Dawson, T. Dawson (Baltimore, USA)

Parkin regulates ER-mitochondria association through interaction with IP3R-Grp75-VDAC1

NJ. Xue, Y. Liu, ZH. Lin, BR. Zhang, JL. Pu (Hangzhou, China)

Pathological Mechanisms Associated with Atrazine-Induced Parkinson’s Disease Pathogenesis in Rat Model: The Rescue Role of Myricetin

C. Ikeji, E. Farombi (Ibadan, Nigeria)

Polyamine pathways: a promising frontier for biomarkers and therapeutic targets in Parkinson’s disease (PD)

W-L. Tsou, P. Lewitt, B. Ranxhi, Z. Chbihi, Z. Bangash, S. Todi (Detroit, USA)

Preclinical Studies: Investigating Serum-Based Exosomal miRNAs in Prodromal Drug-Induced Parkinson’s Disease

M. Ahmad (Hyderabad, India)

Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial

R. Hauser, A. Lang, L. Kalia, JT. Greenamyre, R. Llorens-Arenas, D. Jennings, B. Hersh, K. Fraser, S. Huntwork-Rodriguez, A. Henry, J. Kluss, C. Paisán-Ruiz, Z. Berger (Tampa, USA)

Repurposing Anti-Gout Medications for the Treatment of Parkinson’s Disease

R. Hughes, O. Bandmann, L. Ferraiuolo, H. Mortiboys (Sheffield, United Kingdom)

Role of RNA splicing in Parkinson’s disease

K. Irmady, C. Hale, R. Qadri, J. Fak, T. Carroll, R. Darnell (New York, USA)

Rora deficiency aggravates dopamine neurons loss via reducing NAD+ level in Parkinson’s disease

JW. Li, HS. Liu, XY. Hu, T. Wang, N. Xiong (Wuhan, China)

Serum levels of VEGF-C and ENDGLIN in Parkinson’s disease and their clinical relevance

S. Haji, W. Sako, Y. Osaki, Y. Izumi (Tokushima, Japan)

Simulated Space Gravity Recapitulates Parkinson’s Disease Pathology in Neural Cell Model

V. Lentini, G. Uras, A. Manca, M. El Faqir, S. Lucas, A. Schapira, A. Pantaleo (Sassari, Italy)

Single cell transcriptomics of peripheral blood mononuclear cells and associations with clinical outcomes in Parkinson’s disease

J. Wallin, B. Yaghmaeian Salmani, K. Tiklova, L. Gillberg, H. Green, T. Perlmann, P. Svenningsson (Solna, Sweden)

Sphingomyelinase Activity in Patients with Sporadic Parkinson’s Disease

A. Rekik, A. Mili, S. Naija, E. Jarrar, K. Jemai, A. Hassine, S. Ben Amor, J. Ben Abdallah (Sousse, Tunisia)

Studying digenic Parkinson’s disease in a stem cell model carrying mutant p.N409S in the GBA1 gene and the homozygous deletion of exon 3 PARK2

C. Oleksy, Z. Hanss, F. Massart, G. Arena, I. Boussaad, R. Krüger (Belvaux, Luxembourg)

The functional and lipidome signature of GBA1 mutant dopaminergic neurons

G. Uras, S. Lucas-Del-Pozo, F. Fierli, S. Koletsi, V. Lentini, P. Caboni, C. Manis, D. Di Lisa, A. Andolfi, L. Pastorino, A. Schapira (London, United Kingdom)

The Impact of VPS35 D620N Mutation on Alternative Autophagy and its Reversal by Estrogen in Parkinson’s Disease

T. Shiraishi, K. Bono, Y. Iguchi, H. Okano (Minato-ku, Japan)

The LRRK2 I1371V mutation alters membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD Patient iPSCs

R. Banerjee, V. Holla, N. Kamble, R. Yadav, P. Pal, I. Datta (Bengaluru, India)

The Protective Role of Lysosomal Damage Response in Preventing α-Synuclein Propagation

K. Kakuda, K. Ikenaka, C. Aguirre, C. Choong, Y. Kimura, J. Doi, H. Mochizuki (Suita, Japan)

The role of extracellular vesicles in the progression of Parkinson’s disease

T. Tsunemi, Y. Ishiguro, A. Yoroisaka, T. Shimada, F. Feng, W. Akamatsu, N. Hattori (Tokyo, Japan)

The role of LRRK2 in regulating microglial activity in Parkinson’s disease

S. Brooker, A. Thomas, D. Krainc (Chicago, USA)

TM9SF2 Knockdown Decreases Pathological Alpha-synuclein Aggregation In Vivo

C. Sortwell, R. Kumaran, F. Manfredsson, C. Kemp, M. Benskey, J. Patterson, A. Stoll, J. Howe, N. Kuhn, K. Luk, M. Cookson (Grand Rapids, USA)

Transcriptomic and Proteomic Profiling for Effective Deep Brain Stimulation in Parkinson’s Disease

L. Luo, M-Y. Lai, D. Palanisamy, B. Benitez (Boston, USA)

Understanding the neuroprotective mechanism of ilex Paraguariensis (Yerba mate) in a Drosophila melanogaster alpha-synuclein model of Parkinson’s disease

A. Tschopp, P. Ballestero, G. Decurgez, H. Hauche, T. Eidelman, M. Bordone, N. Muraro, J. Ferrario (CABA, Argentina)

Untargeted Serum Metabolomics Identifies Glycine-Serine Metabolism Disruption as Biochemical Bignature in Parkinson’s Disease

A. Imarisio, C. Marino, M. Avenali, G. Buongarzone, M. Picascia, T. Nuzzo, C. Gasparri, F. Errico, M. Grimaldi, MC. Monti, A. Filosa, M. Rondanelli, C. Pacchetti, AM. D'Ursi, A. Usiello, EM. Valente (Pavia, Italy)